Lp(a) — research review 1

...so it’s a specific type of lipoprotein, often called Lp(a) – that’s L-P-parentheses-A-parentheses. It’s essentially an inherited cardiovascular risk particle.

Inherited, you say? So it's not something we can necessarily control through diet and exercise in the same way we might influence LDL cholesterol?

Exactly. While a healthy lifestyle is always beneficial, Lp(a) levels are largely genetically determined. Think of it as an additional, independent risk factor for cardiovascular disease.

And why are longevity scientists particularly interested in something inherited? If we can't change it, what's the angle for extending healthspan?

Because understanding risk is the first step to mitigating it. Even if the level itself is inherited, the downstream effects might be addressable. Elevated Lp(a) significantly increases the risk of heart attack and stroke, often prematurely. For example, a study in JAMA Cardiology in 2018 highlighted its strong association with early-onset cardiovascular events.

So, identifying those with high Lp(a) allows for more targeted prevention or earlier intervention, even if we're not directly lowering the Lp(a) itself yet?

Precisely. And that's the "yet" part. While we don't have widely available treatments specifically designed to lower Lp(a) for the general population right now, research is actively exploring therapies. However, what remains less clear is the exact mechanism by which Lp(a) contributes to disease in every individual, and precisely how much it needs to be lowered to reduce risk. These are active areas of investigation.